Home/Pipeline/HSF1 Activator Program

HSF1 Activator Program

Neurodegenerative Diseases

Pre-clinicalActive

Key Facts

Indication

Neurodegenerative Diseases

Phase

Pre-clinical

Status

Active

Company

Sisu Pharma

About Sisu Pharma

Sisu Pharma is a private, preclinical-stage biotech founded in 2018 and based in San Diego, California. The company is pioneering a novel therapeutic strategy by directly targeting the transcription factor HSF1, a historically 'undruggable' master regulator of cellular stress protection. Its proprietary HI-LiTe platform enables the discovery of compounds that can either degrade or activate HSF1, with applications in oncology, neurodegeneration, and infection. Led by a team of seasoned scientists and drug developers, Sisu is advancing first-in-class compounds that have shown exceptional efficacy in resistant cancer models.

View full company profile

Therapeutic Areas

Oncology Neurodegenerative Diseases Infectious Diseases

Other Neurodegenerative Diseases Drugs

Drug	Company	Phase	Status
Undisclosed	Modulo Bio	Discovery	Active
PBI-01207	Phoenix Biotechnology	Pre-clinical	Active
Therapeutic Target Discovery Platform	ValtedSeq	Discovery	Active
Undisclosed Neurology Program(s)	Base4	Preclinical	Active
Platform Application for Neurodegenerative Diseases	ALTUCELL	Pre-clinical/Research	Active
OGG1 Activator Program	Luciole Pharmaceuticals	Pre-clinical	Active
Lysosome Biology Program	Talisman Therapeutics	Preclinical	Active
Microglial Health Program	Talisman Therapeutics	Preclinical	Active
Platform-derived candidates	VRG Therapeutics	Pre-clinical	Active
Neurodegenerative Biomarkers R&D	Firalis	Development	Active
Neurodegeneration Pipeline	Origenis	Preclinical	Active
Enhanced Brain Delivery (EBD™) Platform	Acumen Pharmaceuticals	Preclinical	Research Stage